Compare Repligen Corporation Common Stock (RGEN) vs YPF Sociedad Anonima American Depositary Shares (YPF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs YPF Sociedad Anonima American Depositary Shares — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while YPF Sociedad Anonima American Depositary Shares trades at $52.58 (market cap $20.31B). The key difference: YPF Sociedad Anonima American Depositary Shares is the larger of the two by market cap, and Repligen Corporation Common Stock is more actively traded (1,259,263 versus 1,015,599). Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and YPF Sociedad Anonima American Depositary Shares for 6 Days on average.
| RGEN | YPF | |
|---|---|---|
Market Cap | $11.14B | $20.31B |
Volume | 1,259,263 | 1,015,599 |
Sector | Health | Energy |
52-Week High | $194.57 | $57.61 |
52-Week Low | $102.87 | $24.71 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $28.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
YPF trades at $51.79, down 0.35% on the day, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with Q2 2026 earnings beating estimates and strong revenue growth from $18.3B in 2025 to $20.6B projected for 2026. Recent developments include a $24B LNG project gaining U.S. financing support and record quarterly cash flow generation.
The outlook remains positive with analyst consensus at Buy (46.7%) and a $56.67 price target representing 9.4% upside. Key risks include political uncertainty in Argentina and execution challenges for major capital projects. The stock offers value with attractive EV/EBITDA of 3.91x but faces margin pressure from high tax burdens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About YPF Sociedad Anonima American Depositary Shares
YPF is an integrated energy company in Argentina. Its operations span oil and gas exploration and production, transportation, refining, and the marketing of petroleum products.
Read more on YPF →
